MX2020011269A - Dispositivo de administración transdérmica de tetrabenazina. - Google Patents

Dispositivo de administración transdérmica de tetrabenazina.

Info

Publication number
MX2020011269A
MX2020011269A MX2020011269A MX2020011269A MX2020011269A MX 2020011269 A MX2020011269 A MX 2020011269A MX 2020011269 A MX2020011269 A MX 2020011269A MX 2020011269 A MX2020011269 A MX 2020011269A MX 2020011269 A MX2020011269 A MX 2020011269A
Authority
MX
Mexico
Prior art keywords
tetrabenazine
transdermal delivery
delivery device
adhesive
combination
Prior art date
Application number
MX2020011269A
Other languages
English (en)
Spanish (es)
Inventor
Hock S Tan
Suresh Borsadia
Kalpana Patel
Original Assignee
Shinkei Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shinkei Therapeutics Llc filed Critical Shinkei Therapeutics Llc
Publication of MX2020011269A publication Critical patent/MX2020011269A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020011269A 2018-04-25 2019-04-24 Dispositivo de administración transdérmica de tetrabenazina. MX2020011269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862662456P 2018-04-25 2018-04-25
PCT/US2019/028900 WO2019209940A1 (en) 2018-04-25 2019-04-24 Tetrabenazine transdermal delivery device

Publications (1)

Publication Number Publication Date
MX2020011269A true MX2020011269A (es) 2020-12-11

Family

ID=68295781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011269A MX2020011269A (es) 2018-04-25 2019-04-24 Dispositivo de administración transdérmica de tetrabenazina.

Country Status (15)

Country Link
US (2) US12144899B2 (https=)
EP (1) EP3784237B1 (https=)
JP (1) JP7386544B2 (https=)
KR (1) KR102952482B1 (https=)
CN (1) CN112165942B (https=)
AU (1) AU2019261403B2 (https=)
BR (1) BR112020021700A2 (https=)
CA (1) CA3097189A1 (https=)
DK (1) DK3784237T3 (https=)
ES (1) ES2968827T3 (https=)
IL (1) IL278185B2 (https=)
MX (1) MX2020011269A (https=)
TW (1) TWI832854B (https=)
WO (1) WO2019209940A1 (https=)
ZA (1) ZA202006415B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3784237B1 (en) 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
US20220362165A1 (en) * 2019-10-22 2022-11-17 Shinkei Therapeutics Llc Tetrabenazine transdermal delivery device
IL296624A (en) * 2020-03-30 2022-11-01 Shinkei Therapeutics Inc Transdermal delivery of dextromethorphan
CN116036055A (zh) * 2023-03-16 2023-05-02 上海世领制药有限公司 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63313723A (ja) 1987-06-16 1988-12-21 Nitto Electric Ind Co Ltd 外用貼付剤
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JP4988080B2 (ja) * 1997-09-05 2012-08-01 日東電工株式会社 経皮吸収型製剤
IL135258A0 (en) 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
WO2002024157A2 (en) * 2000-09-19 2002-03-28 National Starch And Chemical Investment Holding Corporation Acryl adhesive useful in transdermal drug delivery systems
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
TW200628175A (en) 2004-10-08 2006-08-16 Noven Pharma Transdermal drug delivert device including an occlusive backing
WO2006053067A2 (en) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders
GB0514501D0 (en) 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
WO2010044981A2 (en) 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2771539A1 (en) 2009-08-12 2011-02-17 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenzine
DE102010024105A1 (de) 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
EP2872126B1 (en) * 2012-07-16 2017-12-06 Grünenthal GmbH Pharmaceutical patch for transdermal administration of tapentadol
US9682068B2 (en) 2013-05-20 2017-06-20 Mylan Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
EA201691512A1 (ru) 2014-01-27 2017-01-30 Оспекс Фармасьютикалз, Инк. Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2
NZ760790A (en) 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
WO2015171802A1 (en) * 2014-05-06 2015-11-12 Neurocrine Biosciences, Inc. Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
AR098771A1 (es) * 2014-12-16 2016-06-15 Amarin Tech S A Un dispositivo para la administración transdérmica de rotigotina
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
EA036837B1 (ru) 2015-06-23 2020-12-25 Нейрокрин Байосайенсиз, Инк. Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN107028916B (zh) * 2016-02-04 2020-05-12 北京泰德制药股份有限公司 含有布比卡因或其药用盐的皮肤外用制剂
ITUB20161016A1 (it) * 2016-02-24 2017-08-24 Emenem Srl Composizioni farmaceutiche o cosmetiche comprendenti un polimero e un promotore di assorbimento per il rilascio controllato di principi attivi
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018140092A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
CN110678181A (zh) 2017-04-01 2020-01-10 阿德普蒂奥制药有限公司 (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
US20190111035A1 (en) 2017-04-01 2019-04-18 Adeptio Pharmaceuticals Limited Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
TWI741168B (zh) * 2017-04-28 2021-10-01 日商日東電工股份有限公司 經皮吸收製劑
WO2019016357A1 (en) 2017-07-20 2019-01-24 Neurolixis USE OF SELECTIVE 5-HT1A SEROTONIN RECEPTOR AGONISTS TO TREAT THE ADVERSE EFFECTS OF VMAT INHIBITORS
GB2565049B (en) 2017-07-27 2020-06-10 Reckitt Benckiser Health Ltd A head assembly of a dermaplaning device
JP2021502959A (ja) 2017-10-10 2021-02-04 ニューロクライン バイオサイエンシーズ,インコーポレイテッド 特定のvmat2インヒビターを投与するための方法
EP3784237B1 (en) 2018-04-25 2023-11-01 Shinkei Therapeutics, Inc. Tetrabenazine transdermal delivery device
US20190374521A1 (en) 2018-06-10 2019-12-12 Axsome Therapeutics, Inc. Methods of modulating tetrabenazine metabolites plasma levels using bupropion
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.

Also Published As

Publication number Publication date
KR102952482B1 (ko) 2026-04-13
ES2968827T3 (es) 2024-05-14
ZA202006415B (en) 2024-04-24
TW202014187A (zh) 2020-04-16
BR112020021700A2 (pt) 2021-01-26
KR20210005623A (ko) 2021-01-14
IL278185A (https=) 2020-12-31
EP3784237A1 (en) 2021-03-03
EP3784237A4 (en) 2022-02-16
TWI832854B (zh) 2024-02-21
IL278185B2 (en) 2024-11-01
WO2019209940A1 (en) 2019-10-31
AU2019261403A1 (en) 2020-11-12
US20250144045A1 (en) 2025-05-08
CN112165942A (zh) 2021-01-01
US20210128490A1 (en) 2021-05-06
DK3784237T3 (da) 2024-01-08
CA3097189A1 (en) 2019-10-31
JP7386544B2 (ja) 2023-11-27
AU2019261403B2 (en) 2025-05-15
CN112165942B (zh) 2024-04-12
US12144899B2 (en) 2024-11-19
JP2021522240A (ja) 2021-08-30
IL278185B1 (en) 2024-07-01
EP3784237B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
ZA202006415B (en) Tetrabenazine transdermal delivery device
PH12018502738A1 (en) Compositions, devices, and methods for the treatment of alcohol use disorder
MX2022010168A (es) Moduladores de calpainas y usos terapeuticos de los mismos.
EP4349735A3 (en) Packages for medical devices
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
MX2017003623A (es) Parche de opipramol.
MX2019005833A (es) Administracion transdermica de agentes grandes.
BR112018008103A2 (pt) análogos de celastrol
DK3706841T3 (da) Kanyleskjoldsfjerner og medikamentafgivelsesindretning, der omfatter kanyleskjoldsfjerneren
MA40473A (fr) Dispositifs d'administration de médicaments à base d'une silicone catalysée par du platine, et leurs procédés d'utilisation
BR112016001781A2 (pt) inibidores de rorc2 e métodos de uso dos mesmos
EP3691641A4 (en) DEXTROMETHORPHANE DEVICE FOR TRANSDERMAL ADMINISTRATION
MX372702B (es) Una composicion antimicrobiana.
FI20165932L (fi) Immunomodulatorisia koostumuksia
EP3389760A4 (en) ELECTROKINETIC TRANSDERMAL AND TRANSMUCOSAL DELIVERY DEVICE
UA122329C2 (uk) Комплекс лікарський засіб-пристрій з вмістом хінаголіду
EP3434314A4 (en) TRANSDERMAL DELIVERY SYSTEM
MX2021015026A (es) Peptido derivado de urlc10 y vacuna que lo contiene.
EP4048268A4 (en) DEVICE FOR TRANSDERMAL ADMINISTRATION OF TETRABENAZINE
GEAP202115006A (en) Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof
MX2018009739A (es) La administración combinada de un agente de penetración y un compuesto que contiene azufre a plantas.
PH12017501563A1 (en) Oligomeric/polymeric silicone fluids for use in transdermal drug delivery systems
EP3766536A4 (en) MEDICATION DELIVERY DEVICE, APPARATUS AND SET
TW201613952A (en) Cdca1-derived peptide and vaccine containing same